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The authors investigated the association between contrastinduced nephropathy (CIN) and mortality in patients with acute myocardial infarction (AMI) but they did not mention about subgroups such as ongoing ST-segment elevation myocardial infarction (STEMI), ongoing non-STEMI, and stabilized AMI. Recently, de Mulder et al 2 have proposed a new risk stratification flowchart for predicting poor outcomes for patients undergoing percutaneous coronary interventions (PCIs). According to this study, stabilized AMI suggests a benign condition, whereas ongoing STEMI and ongoing non-STEMI suggest a serious condition. In addition, we have previously reported that contrast media volume-estimated glomerular filtration rate (CV-e-GFR) ratio was significantly associated with CIN after primary PCI. 3 Did the authors find any association between CV-e-GFR and CIN in patients with STEMI?
Furthermore, the authors did not explain whether patients with severe chronic lung disease were included or excluded. The National Cardiovascular Data Registry for catheterization PCI showed that chronic lung disease was a predictor of longterm mortality following PCI. 4 Recently, it was reported that statins administered at high dose may be the most effective treatment to reduce the incidence of CIN. 5 Were statins used for prevention in that study? It would be useful if the authors mention about this treatment.
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